Arrowhead Pharmaceuticals, Inc. (ARWR) - Stock Analysis
Last updated: Jan 19, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Near-term growth opportunity following FDA approval of REDEMPLO (first siRNA therapy for familial chylomicronemia syndrome), Breakthrough Therapy designation for another indication, $200M Novartis upfront payment, and 32.7% price surge supported by strong technical breakout.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong cash generation ⢠High R&D burden ⢠Significant leverage ARWR generates strong cash flow and solid operating margins with ample liquidity but faces material solvency risk from high longâterm debt, outsized R&D/OPEX pressure on net earnings, and richly stretched valuation.
Price Behavior
Key Price Behavior Insights: ⢠Mid-60s support ⢠Resistance ~70.8 ⢠Recent consolidation Support Level: $60â$65 Resistance Level: $70.80 Over the last month, ARWR showed volatile but overall strong upward momentum that has recently consolidated around the mid-$60s, with resistance near $70.80 and support roughly $60â$65, indicating buyers stepping in at mid-60s but risk of a short-term pullback.
Sentiment & News
Key News Insights: ⢠Regulatory approvals ⢠Promising RNAi data ⢠Large capital raise Arrowhead posted regulatory wins for REDEMPLOâ˘, encouraging early RNAi obesity data, and launched a large convertible-note and equity raise amid mixed insider and institutional trading.
AI Summary
Arrowhead's transformation into a commercial-stage company means investment returns now hinge less on trial binaries and more on commercial executionâspecifically REDEMPLO's payer coverage, real-world uptake, and milestone-driven cash converting into repeatable product revenue to avoid further dilutive financings. Monitor REDEMPLO reimbursement wins, early sales trends vs. management guidance, and convertible-note conversion triggers as the decisive indicators of upside or forced dilution.
Description
Arrowhead Pharmaceuticals is a Pasadena-based biopharmaceutical company, founded in 1989, that develops RNA interference therapeutics for a range of liver, cardiovascular, pulmonary, rare genetic and oncology indications. Its clinical-stage pipeline includes candidates targeting liver-expressed proteins, cardiovascular lipid regulators, pulmonary targets and other disease-specific genes, and the company partners with Janssen and Takeda on several liver-directed programs. Arrowhead also participates in collaborations for subcutaneously administered RNAi candidates for chronic hepatitis B and other externally developed programs.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 2 | Dec 9 | ARWR | Arrowhead Pharmaceuticals, Inc. | Near-term growth opportunity following FDA approval of REDEMPLO (first siRNA therapy for familial chylomicronemia syndrome), Breakthrough Therapy designation for another indication, $200M Novartis upfront payment, and 32.7% price surge supported by strong technical breakout. | Closed | +18.8% |